Novartis presents latest Phase III Fabhalta® (iptacopan

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Related Keywords

Denmark , Stockholm , Sweden , Praga , Praha , Hlavníesto , Czech Republic , United States , Danish , America , Parag Mahanti , David Soergel , Prnewswire Novartis , Marianne Silkj , Marlena Abdinoor , Jonathan Graham , David Kavanagh , Sloan Simpson , Instagram , Faculty Of Medical Sciences At Newcastle University , University Of Washington , G Steering Committee Member , Metabolism Development Unit , Novartis , European Renal Association , Novartis Pharmaceuticals Corporation , Linkedin , Exchange Commission , Glomerular Diseases Work Group , Facebook , Professor David Kavanagh , Complement Therapeutics , Honorary Consultant Nephrologist , Medical Sciences , Newcastle University , Steering Committee , Global Head , Parallel Group , Placebo Controlled Study , Accessed May , Complement Pathway Inhibition , Study Design , Kidney Int , Narrative Review , Rare Renal , Intj Mol , Dense Deposit , Rare Complement Driven Renal , Nat Rev , Hemolytic Uremic Syndrome , Improving Global , Improving Global Outcomes , Glomerular Diseases Work , Practice Guideline , Iga Nephropathy , Interim Results , Primary Iga Nephropathy Patients , Open Label Trial , Evaluate Efficacy , Twice Daily , Who Are Naive , Complement Inhibitor Therapy , Surrogate End Point , Clinj Am Soc , Kidney Outcomes , Nephrol Dial , Endpoint Analysis , Atrasentan Shows Significant Reduction , Primary Iga Nephropathy , Interim Analysis Results , Long Term Safety , Month Extension Study Data , Patients Enrolled , Good Tolerability , Dose Exploration , Placebo Controlled , Multicenter Phase , Oral Corticosteroids , Nephritis Class , Clinicopathologic Features , Genetic Complement Abnormalities Play , Critical Role , Dense Deposit Disease , Immune Complex ,